Bay Area's Pionyr Immunotherapeutics Scores $62M to Push Anti-Tumor Tech Towards Clinic Post author:Sam Post published:December 12, 2017 Post category:BioPharma Pionyr was founded in 2015 by a UCSF professor and a Genentech alum. Source: BioSpace You Might Also Like MyoKardia Sees Positive Results in Mid-Stage Heart Trial March 8, 2018 Data To Be Presented At Highlighting GENFIT???s Latest Progress In NASH Biomarker Diagnostics, Identifying Novel Compounds With Potent Antifibrotic Properties, And Illustrating The Opportunities In Anti-NASH Drug Combinations April 4, 2017 AstraZeneca Continues to Divest Assets, Takes Stake in Mereo BioPharma With New Deal October 29, 2017
Data To Be Presented At Highlighting GENFIT???s Latest Progress In NASH Biomarker Diagnostics, Identifying Novel Compounds With Potent Antifibrotic Properties, And Illustrating The Opportunities In Anti-NASH Drug Combinations April 4, 2017
AstraZeneca Continues to Divest Assets, Takes Stake in Mereo BioPharma With New Deal October 29, 2017
